While many countries are scrambling to roll out vaccine boosters in hopes of reducing hospitalisation when the “viral blizzards” of Omicron begin to hit, Israel has already approved fourth shots for vulnerable groups. This comes just a year after the country rolled out its vaccination campaign with Pfizer/BioNTech mRNA jabs, and about five months after a third, booster shot roll-out..
Apr 15, 2021
The call came early in the COVID-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
The technology, which effectively turns the body’s cells into tiny vaccine-making factories, has since become the breakout star of the COVID-19 era, underpinning shots made by Moderna Inc. and the Pfizer Inc./BioNTech SE partnership which have been among the most effective in fighting the disease. Before the coronavirus hit, though, the experimental science had yet to receive regulatory approval for use against any illness let alone against the mysterious infection.
âI never heard from them againâ: A missed vaccine opportunity has left Chinese companies scrambling
Weâre sorry, this service is currently unavailable. Please try again later.
Dismiss
By Bruce Einhorn
Save
Normal text size
Advertisement
The call came early in the COVID-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
mRNA, which effectively turns the bodyâs cells into tiny vaccine-making factories, has since become the breakout star of the COVID era, underpinning shots made by Moderna and the Pfizer/BioNTech partnership which have been among the most effective in fighting the disease. Before COVID hit, though, the experimental science had yet to receive regulatory approval for use against any illness - let alone against the mysterious respiratory infection.
How China fell behind after passing up a vaccine opportunity japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.
How China Passed Up a Vaccine Opportunity and Fell Behind Bloomberg 2 hrs ago Bruce Einhorn
(Bloomberg) The call came early in the Covid-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
mRNA, which effectively turns the body’s cells into tiny vaccine-making factories, has since become the breakout star of the Covid era, underpinning shots made by Moderna Inc. and the Pfizer Inc./BioNTech SE partnership which have been among the most effective in fighting the disease. Before Covid hit, though, the experimental science had yet to receive regulatory approval for use against any illness let alone against the mysterious respiratory infection.